All In MedTech

FDA Clearance Tracker · P020014-S017

CONCEPTUS ESSURE SYSTEM FOR PERMANENT BIRTH CONTROL

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 24, 2012 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 24, 2012

Approved

Time to decision

1,421 days

Received Apr 4, 2008. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P020014-S017
Device name
CONCEPTUS ESSURE SYSTEM FOR PERMANENT BIRTH CONTROL
Applicant location
Berlin
Received
Apr 4, 2008
Decided
Feb 24, 2012
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P020014

Device type

Device class
Class III
Regulation
21 CFR 884.5380

Every decision under product code HHS

FDA's approval statement

As written in FDA's record.

APPROVAL TO MODIFY THE EXISTING RF ENERGY WARNING TO ADD AN ESSURE/ NOVASURE WARNING. ADDITIONALLY, THE PMA SUPPLEMENT INCLUDES APPROVAL OF A POST-APPROVAL STUDY.

Source documents

Other decisions for Bayer Pharma AG

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.